JORGE PLUTZKY, MD
Osteopathic Medicine in Boston, MA

2013025, Sep 26, 2013

May 16, 2011

13/697963

James Elliott Bradner - Boston MA, US
Jonathan Brown - Brookline MA, US
Jorge Plutzky - Chestnut Hill MA, US

C07D 495/14, A61K 31/7088

435375, 514220, 540560

The invention provides compositions comprising an effective amount of an agent that inhibits a BET protein (e.g., Brd2, Brd3, Brd4), and methods of using such compositions for treating or preventing metabolic syndrome, obesity, type II diabetes, insulin resistance, and related disorders characterized by undesirable alterations in metabolism or fat accumulation.

2011004, Feb 24, 2011

Feb 27, 2009

12/919716

Jorge Plutzky - Chestnut Hill MA, US
Ouliana Ziouzenkova - Columbus OH, US

THE BRIGHAM AND WOMEN'S HOSPITAL, INC. - Boston MA

A61K 31/11, A61P 3/10, A61P 3/04, A61P 35/00, A61P 9/10

514703

The present invention is directed to methods of treating a patient for a disease or condition associated with adipogenesis or insulin resistance by administering a retinaldehyde compound to the patient or a compound that increases endogenous retinaldehyde levels by inhibiting the enzyme retinaldehyde dehydrogenase 1.

2005012, Jun 16, 2005

Feb 4, 2005

11/049649

Jorge Plutzky - Brookline MA, US
Ouliana Ziouzenkova - Brookline MA, US

A61K007/025, A61K007/06, A61K007/11, A61K038/46

424401000, 424094600, 424064000, 424070140

The present invention is directed to compositions which include the enzyme lipoprotein lipase. These compositions may be applied topically to the skin of a person to prevent dryness or treat inflammation. In addition, the invention is directed to the use of fibrates to enhance the activity of lipoprotein lipase. The fibrates may be used orally to treat inflammation or enhance metabolic energy production.

2002003, Mar 14, 2002

Aug 29, 2001

09/940858

Jorge Plutzky - Brookline MA, US
Ouliana Ziouzenkova - Brookline MA, US

The Brigham and Women's Hospital, Inc.

A61F013/00, A61K009/70, A61K009/20

424/422000, 424/434000, 424/449000

The present invention is directed to certain oxidized forms of retinoic acid and their precursors that have been found to be effective in treating conditions that respond to agents that bind to and activate the human peroxisome proliferator activated receptor-gamma. Specific compounds include oxidized all-trans retinoic acid; oxidized 9-cis retinoic acid; and reduced 4-oxo-retinoic acid. The compounds may be used in treating a number of diseases or conditions including diabetes, low body weight, atherosclerosis, and certain forms of cancer.

6869603, Mar 22, 2005

Nov 7, 2002

10/289203

Jorge Plutzky - Brookline MA, US
Ouliana Ziouzenkova - Brookline MA, US

The Brigham and Women's Hospital, Inc. - Boston MA

A61K038/46

424 946, 424522, 424725

The present invention is directed to compositions which include the enzyme lipoprotein lipase. These compositions may be applied topically to the skin of a person to prevent dryness or treat inflammation. In addition, the invention is directed to the use of fibrates to enhance the activity of lipoprotein lipase. The fibrates may be used orally to treat inflammation or enhance metabolic energy production.

5536636, Jul 16, 1996

Feb 28, 1994

8/202389

Robert M. Freeman - Boston MA
Jorge Plutzky - Boston MA
Benjamin G. Neel - Wayland MA
Robert D. Rosenberg - Brookline MA

Beth Israel Hospital - Boston MA
Massachusetts Institute of Technology - Cambridge MA

C07H 2164, C12P 1934, C12Q 168

435 6

The present invention relates to the isolation of genes encoding novel protein tyrosine phosphatases (PTPs) having SH2 domains, the nucleic acid sequences isolated, and the encoded phosphatases. The invention further relates to methods of altering tyrosine phosphatase activities encoded by the novel phosphatases. By altering (i. e. , increasing or decreasing) tyrosine phosphatase activity, one can alter megakaryocyte cell function, and thereby alter platelet production. Alteration of the genes is associated with neoplastic disease.